Cargando…
Twelve years of European cancer drug approval—a systematic investigation of the ‘magnitude of clinical benefit’
BACKGROUND: The magnitude of clinical benefit of solid cancer drugs can be standardly assessed via the Magnitude of Clinical Benefit Scale (MCBS) developed by the European Society for Medical Oncology (ESMO). We applied two ESMO-MCBS versions to the last 12 years of European cancer drug approval and...
Autores principales: | Grössmann, N., Wolf, S., Rothschedl, E., Wild, C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8182388/ https://www.ncbi.nlm.nih.gov/pubmed/34087744 http://dx.doi.org/10.1016/j.esmoop.2021.100166 |
Ejemplares similares
-
Letter comments on: “Twelve years of European cancer drug approval—a systematic investigation of the ‘magnitude of clinical benefit’”
por: Müller, B., et al.
Publicado: (2022) -
Between January 2009 and April 2016, 134 novel anticancer therapies were approved: what is the level of knowledge concerning the clinical benefit at the time of approval?
por: Grössmann, Nicole, et al.
Publicado: (2017) -
Are Quality of Randomized Clinical Trials and ESMO-Magnitude of Clinical Benefit Scale Two Sides of the Same Coin, to Grade Recommendations for Drug Approval?
por: Rodriguez, Adela, et al.
Publicado: (2021) -
Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia
por: Hwang, Thomas J., et al.
Publicado: (2022) -
Pre‐approval and post‐approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: A comparison with standard approved cancer drugs
por: Bloem, Lourens T., et al.
Publicado: (2022)